Safety

Topical dapsone (Aczone) is not on WADA's banned list. Oral dapsone is different: it's a sulfone drug with real risks and needs G6PD testing first.

Topical dapsone needs no blood work. Oral dapsone requires G6PD testing first, plus CBC monitoring. Here's exactly what's checked and when.

Topical dapsone has minimal interaction risk. Oral dapsone interacts with trimethoprim, rifampin, and more, and needs G6PD testing first. Full breakdown.

There's no injectable dapsone. Here's what "injection sites" searches usually mean: topical gel spots, oral pills, and G6PD testing before either.

Topical dapsone gel has mild long-term risks. Oral dapsone can cause hemolysis, methemoglobinemia, and DHS. Here's what the data actually shows.

Topical dapsone (Aczone) mainly causes dryness and mild irritation. Oral dapsone can cause hemolysis and needs G6PD testing first. Here's the real breakdown.

Aczone gel is stable at room temp (59-86°F) for its labeled shelf life; oral dapsone tablets typically expire 2-4 years from manufacture. Full storage rules here.

Topical dapsone (Aczone 5%/7.5%) is FDA approved for acne since 2005. Oral dapsone is approved too, but for different diseases, with far higher risks.

Topical dapsone 5%/7.5% is FDA-approved and low-risk. Oral dapsone can cause hemolysis and needs G6PD testing. Here's the real safety breakdown, with sources.

Topical dapsone 5-7.5% treats acne via anti-inflammatory action. Oral dapsone fights infection but needs G6PD testing. Here's the real mechanism, by form.